Watch also the other lectures

1. Welcome and Introduction
Tony Mok

2. PD1 inhibitors for NSCLC: Where are we now?
Tony Mok

3. One molecule, many mechanisms of action: Why all PD1 inhibitors are not the same
Raffaele Califano

4. How will the new wave of PD1 inhibitors change the treatment landscape in NSCLC?
Anne-Marie C. Dingemans

5. What is the impact of PD1 inhibitors for NSCLC in your clinic? A case study discussion
Tony Mok AND Anne-Marie C. Dingemans

7. Exploring the promise of emerging PD1 inhibitors in NSCLC
Giorgio Scagliotti